Annual ADC and Novel Conjugates Partnering and Investment Summit on September 09-10, 2025 in Boston, United States

Back for its second year, the ADC Partnering and Investment Summit unites 100+ top ADC companies, pharma leaders, and investors for hyper-aligned and more efficient business networking.

Unite with other ADC business development leaders where cutting-edge science meets strategic networking:

- Connect directly with decision-makers in a less competitive setting

- Understand how others are positioning themselves to refine your own differentiation

- Gain insights from scientific pioneers shaping the future of ADCs to define your strategic direction

URLs:

Tickets: https://go.evvnt.com/3117445-2?pid=10008

Brochure: https://go.evvnt.com/3117445-3?pid=10008

Time: 7:50 AM - 4:00 PM

Prices:

Biotech, Pharma and Investors: USD 3099.00,

Academics: USD 2699.00,

Service Providers: USD 5299.00

Speakers: Adrianne Wong, Director, Oncology Search and Evaluation, Global Business Development, Daiichi Sankyo, Ajla Hrle, Chief Business Officer, DISCO Pharmaceuticals, Arne Scheu, Co-Founder and Chief Executive Officer, Valink Therapeutics, Barbara Leyman, Chief Business Officer, Sutro Biopharma, Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics , Brian Zhou, Associate Director, Lily Venture, Caitlyn Miller, Co-Founder and Chief Executive Officer, TwoStep Therapeutics, Carla Bauer, Director, Oncology Search and Evaluation, Business Development, Merck, Chris Hupp, Senior Director, Research and External Innovation, Ipsen, Christoph Korpus, Chief Business Officer, Byondis, Constantine Theodoropulos, Co-Founder and Chief Executive Officer, GO Therapeutics, Cookie Yu, Investment Director, Samsung Venture Investment Corporation, Elena Diez, Senior Director, External Innovation, Johnson and Johnson, Filippo Mulinacci, Chief Business Officer, Araris Biotech, Gilan Megeed, Principal, Deerfield, Greco Song, Associate, Deep Track Capital, Hanspeter Gerber, Chief Scientific Officer, Sutro Biopharma, Harris Weber, Principal, Bain Capital Life Sciences, Hans Wandall, Chief Scientific Officer, GO Therapeutics, Hong Xin, Senior Director, Search and Evaluation, Johnson and Johnson, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences, Jason Ruth, Sector Lead, Biotech Private Investments, Wellington Management, Jenny Wang, Director II, Search and Evaluation Oncology, AbbVie, Joe Nabhan, Chief Scientific Officer, K2B Therapeutics, John Mayfield, Senior Vice President, Business Development and Strategy, Flagship Pioneering, Juanjo Cragnolini, Associate Director, Search and Evaluation, Oncology, Takeda, Kinney Horn, Chief Business Officer, Immunome, Marc Robillard, Founder and Chief Scientific Officer, Tagworks Pharmaceuticals, Matthew Metzger, Program, Alliance and Business Development Manager, Oxford Biotechnologies, Natalie Tucker, Senior Vice President - Radioligand Therapies, Y-mAbs Therapeutics, Patrick Beusker, Director, Medicinal and Protein Chemistry, Byondis, Patrick Zweidler-McKay, Chief Medical Officer, Sidewinder Therapeutics, Robin Carr, Chief Executive Officer, Myricx Bio, Steve Bartz, Head of Oncology Search and Evaluation, Pfizer, Steven Everett, Chief Executive Officer, MaveriX Oncology, Tim Wang, Chief Business Officer, Duality Biologics, Travis Biechele, Vice President, Research, Shasqi, Valerie Vanhooren, Co-founder and Chief Executive Officer, Ona Therapeutics, Weston Kightlinger, Entrepreneur in Residence, Sutter Hill Ventures, Yangzi He, Associate Director, Business Development - Oncology and Hematology, Search and Evaluation, BMS